QIAGEN
Molecular diagnostics leader — QIAstat-Dx, QIAamp extraction kits, and QIAsymphony automation; nucleic acid extraction reagents used in 90% of global CRISPR diagnostics workflows.
- Country
- Netherlands
- Revenue
- $2.0B
- Employees
- ~6,100 emp
ISO 13485
GMP EU
CE-IVD
Coverage
| CN | EU | IN | US | |
|---|---|---|---|---|
| bioinformatics-omics | ✓ | ✓ | ✓ | ✓ |
| diagnostics-medtech | ✓ | ✓ | — | ✓ |
| monitoring-conservation | ✓ | ✓ | — | ✓ |
Regulatorsfdaemanmpausda-aphismoa-chinaefsa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Biological AI & bioinformation services | bioinformatics-omics | Medium | → |
| CRISPR diagnostics | diagnostics-medtech | Medium | → |
| Personalized diagnostics | diagnostics-medtech | Low | → |
| Sovereign genome databases (plants, animals, microbes) | monitoring-conservation | Medium | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.